{"id":"https://openalex.org/W4200464662","doi":"https://doi.org/10.1002/ajh.26444","title":"A multicenter, retrospective study of accelerated venetoclax ramp\u2010up in patients with relapsed/refractory chronic lymphocytic leukemia","display_name":"A multicenter, retrospective study of accelerated venetoclax ramp\u2010up in patients with relapsed/refractory chronic lymphocytic leukemia","publication_year":2021,"publication_date":"2021-12-20","ids":{"openalex":"https://openalex.org/W4200464662","doi":"https://doi.org/10.1002/ajh.26444","pmid":"https://pubmed.ncbi.nlm.nih.gov/34929063"},"language":"en","primary_location":{"id":"doi:10.1002/ajh.26444","doi":"https://doi.org/10.1002/ajh.26444","is_oa":false,"landing_page_url":"https://doi.org/10.1002/ajh.26444","pdf_url":null,"source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":"https://orcid.org/0000-0003-4529-2003","affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051296565","display_name":"Mazyar S. Shadman","orcid":"https://orcid.org/0000-0002-3365-6562","observed_orcids":["https://orcid.org/0000-0002-3365-6562"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mazyar Shadman","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA","Division of Medical Oncology, University of Washington, Seattle, Washington, USA"],"raw_orcid":"https://orcid.org/0000-0002-3365-6562","affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"Division of Medical Oncology, University of Washington, Seattle, Washington, USA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009747339","display_name":"Sameer Ashok Parikh","orcid":"https://orcid.org/0000-0002-3221-7314","observed_orcids":["https://orcid.org/0000-0002-3221-7314"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sameer A. Parikh","raw_affiliation_strings":["Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA"],"raw_orcid":"https://orcid.org/0000-0002-3221-7314","affiliations":[{"raw_affiliation_string":"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079426839","display_name":"Chaitra Shankar Ujjani","orcid":"https://orcid.org/0000-0003-1977-1510","observed_orcids":["https://orcid.org/0000-0003-1977-1510","https://orcid.org/0000-0003-2662-4826"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chaitra Ujjani","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"],"raw_orcid":"https://orcid.org/0000-0003-1977-1510","affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088077600","display_name":"Jennifer Leigh Crombie","orcid":"https://orcid.org/0000-0003-3445-5129","observed_orcids":["https://orcid.org/0000-0003-3445-5129"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer L. Crombie","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"],"raw_orcid":"https://orcid.org/0000-0003-3445-5129","affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113885950","display_name":"Dingfeng Jiang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dingfeng Jiang","raw_affiliation_strings":["AbbVie Inc., North Chicago, Illinois, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, Illinois, USA","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047336376","display_name":"Cynthia Llamas","orcid":"https://orcid.org/0000-0003-0133-2536","observed_orcids":["https://orcid.org/0000-0003-0133-2536"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cynthia Llamas","raw_affiliation_strings":["AbbVie Inc., North Chicago, Illinois, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, Illinois, USA","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086804517","display_name":"Feng Dai","orcid":"https://orcid.org/0000-0002-9963-6863","observed_orcids":["https://orcid.org/0000-0002-9963-6863"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dai Feng","raw_affiliation_strings":["AbbVie Inc., North Chicago, Illinois, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, Illinois, USA","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5010100538","display_name":"Nicole Lamanna","orcid":"https://orcid.org/0000-0003-3331-9491","observed_orcids":["https://orcid.org/0000-0003-3331-9491"]},"institutions":[{"id":"https://openalex.org/I2799503643","display_name":"Columbia University Irving Medical Center","ror":"https://ror.org/01esghr10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799503643"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicole Lamanna","raw_affiliation_strings":["Columbia University Medical Center, New York, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Columbia University Medical Center, New York, New York, USA","institution_ids":["https://openalex.org/I2799503643"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5063755644"],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":0.5559,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.63859721,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"97","issue":"3","first_page":"E105","last_page":"E109"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.9940000176429749},{"id":"https://openalex.org/keywords/relapsed-refractory-chronic-lymphocytic-leukemia","display_name":"relapsed/refractory chronic lymphocytic leukemia","score":0.9909999966621399},{"id":"https://openalex.org/keywords/tumor-lysis-syndrome","display_name":"tumor lysis syndrome","score":0.8370000123977661},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5180000066757202},{"id":"https://openalex.org/keywords/lymphocyte-count","display_name":"lymphocyte count","score":0.3370000123977661},{"id":"https://openalex.org/keywords/renal-function","display_name":"renal function","score":0.5630000233650208},{"id":"https://openalex.org/keywords/nccn-guidelines","display_name":"NCCN guidelines","score":0.4050000011920929},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.3540000021457672},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.4690000116825104}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.9877636432647705},{"id":"https://openalex.org/C2779788671","wikidata":"https://www.wikidata.org/wiki/Q998803","display_name":"Tumor lysis syndrome","level":3,"score":0.769692599773407},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7390913367271423},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.5799381136894226},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.5680304765701294},{"id":"https://openalex.org/C2779260929","wikidata":"https://www.wikidata.org/wiki/Q5908266","display_name":"Idelalisib","level":5,"score":0.5107994079589844},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5027875900268555},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4874594211578369},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47618380188941956},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4233304560184479},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.32591956853866577},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3057754635810852},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019086","descriptor_name":"Bridged Bicyclo Compounds, Heterocyclic","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1002/ajh.26444","doi":"https://doi.org/10.1002/ajh.26444","is_oa":false,"landing_page_url":"https://doi.org/10.1002/ajh.26444","pdf_url":null,"source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},{"id":"pmid:34929063","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34929063","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American journal of hematology","raw_type":"Letter"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[{"id":"https://openalex.org/G9000897310","display_name":"Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology","funder_award_id":"K12CA087723","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320309117","display_name":"AbbVie","ror":"https://ror.org/02g5p4n58"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":6,"referenced_works":["https://openalex.org/W2192121806","https://openalex.org/W2773047201","https://openalex.org/W2792666902","https://openalex.org/W2808653175","https://openalex.org/W2948436219","https://openalex.org/W3092565633"],"related_works":["https://openalex.org/W7165646658","https://openalex.org/W4379339452","https://openalex.org/W4385628144","https://openalex.org/W2982781971","https://openalex.org/W2753631200","https://openalex.org/W4392232649","https://openalex.org/W3092565633","https://openalex.org/W2808653175","https://openalex.org/W2764322962","https://openalex.org/W7171810840"],"abstract_inverted_index":{"The":[0,225,242,514,540,583,1019,1255,1398,2209],"efficacy":[1],"of":[2,24,37,50,118,149,165,176,248,265,297,330,334,343,359,371,377,503,509,542,553,569,571,580,591,614,628,637,657,671,684,691,744,753,756,760,768,968,1028,1041,1060,1082,1094,1115,1133,1136,1142,1145,1151,1154,1162,1164,1182,1192,1205,1212,1224,1239,1244,1263,1288,1303,1321,1369,1378,1388,1393,1396,1400,1436,1459,1469,1475,1491,1505,1510,1542,1556,1620,1647,1654,1668,1681,1686,1740,1751,2001,2029,2034,2037,2042,2104,2149,2160,2219],"venetoclax":[3,92,129,150,168,214,266,348,378,392,485,515,592,978,1042,1172,1200,1215,1245,1264,1493,1535,1579,1656],"in":[4,54,151,171,192,267,274,283,350,521,749,1070,1234,1286,1309,1332,1406,1497,1539,1552,1573,1603,1614,1623,1658,1699,1722,1745,1885,1995,2136],"chronic":[5],"lymphocytic":[6],"leukemia":[7],"(CLL)":[8],"is":[9,13,30,67,77,1559,1660,1696,1711,1719,1890,2061,2211],"well":[10,2086],"established.1-3":[11],"Venetoclax":[12,1000,1717],"approved":[14,1261,1416],"with":[15,72,82,123,173,201,250,624,641,781,992,1130,1179,1194,1198,1347,1390,1414,1530,1544,1562,1584,1632,2183],"a":[16,35,47,115,211,261,328,493,506,550,566,611,765,1356,1456,1540,1553,1598,1697,1714,1891,2150,2161,2196],"5-week":[17,65,1417,1612],"dose":[18,49,117,376,495,508,568,579,590,613,1059,1262,1333,1359],"ramp-up":[19,66,169,215,232,240,349,504,516,551,621,649,1168,1201,1280,1334,1418,1438,1494,1536,1580,1600,1613,1657],"schedule":[20,36,170,1419,1495,1601],"to":[21,34,91,112,159,198,259,487,586,794,813,823,888,920,995,1003,1171,1176,1221,1227,1231,1258,1328,1375,1442,1448,1464,1501,1512,1664,1735,1758,1869,1941,1990,2063,2076,2194,2236],"mitigate":[22],"risk":[23,967,1027,1132,1320,1377,1387,1392,1468],"tumor":[25],"lysis":[26],"syndrome":[27],"(TLS);":[28],"dosing":[29],"increased":[31,829,974,1386],"weekly":[32],"according":[33],"20":[38,573,607,732,1061],"mg,":[39,41,43,45,1005],"50":[40,1004],"100":[42,299],"200":[44,510,734],"reaching":[46],"target":[48,578],"400":[51,581,615,1265],"mg":[52,511,981,1266],"daily":[53],"Week":[55],"5":[56,316,558,1452],"per":[57,131,718,1277],"United":[58,194],"States":[59,195],"prescribing":[60],"information.":[61,2206],"Although":[62,1548],"this":[63,268,1185,1648],"standard":[64,1279,1563,1611],"appropriate":[68,1364],"for":[69,79,98,145,605,715,1318,1335,1521,1768,1882,1911,2045,2114,2118,2180,2214,2240],"most":[70],"patients":[71,81,89,122,172,249,278,289,309,352,365,384,395,408,482,525,544,563,574,608,618,643,677,697,724,758,952,1064,1095,1104,1193,1213,1336,1346,1460,1499,1543,1557,1583,1594,1622],"CLL,":[73,1586],"rapid":[74,147,174,1351,1358,1394,1470],"disease":[75,1352,1471],"control":[76,1353],"needed":[78],"some":[80],"very":[83],"aggressive":[84,986,1545,1585],"disease.":[85],"While":[86,1282],"many":[87],"such":[88,109],"respond":[90],"treatment":[93,208,1218],"it":[94],"remains":[95],"critical,":[96],"especially":[97],"those":[99,1232,1412,1588],"who":[100,204,385,609,725,763,956,1096,1105,1461,1595,2134],"progress":[101],"on":[102,143,654,2190],"B-cell":[103],"receptor":[104],"pathway":[105],"inhibitor":[106],"(BCRi)":[107],"therapies":[108],"as":[110,622,963,1023,2085,2087,2096,2098],"ibrutinib,":[111],"rapidly":[113],"achieve":[114],"therapeutically-relevant":[116],"venetoclax.4":[119],"Thus,":[120,1577],"certain":[121],"CLL":[124,203,335,1196,1349,1659],"might":[125],"benefit":[126,1582],"from":[127,196,222,1433,1702,1871],"expedited":[128],"ramp-up,":[130,257,530,1564],"National":[132],"Comprehensive":[133],"Cancer":[134],"Network":[135],"Clinical":[136,1380,1700,2093],"Practice":[137],"Guidelines.":[138],"Limited":[139],"data":[140,1343,1642,1818,2065,2081,2083,2117,2126,2176],"are":[141,272,519,2101],"available":[142],"strategies":[144],"more":[146,1339,1357,1607,2188],"escalation":[148],"CLL.5":[152],"We":[153],"report":[154,1454],"the":[155,161,193,246,284,374,543,577,606,655,712,722,741,750,777,950,983,1007,1056,1116,1137,1180,1217,1249,1260,1274,1278,1312,1384,1391,1415,1484,1489,1492,1502,1506,1508,1604,1610,1615,1621,1666,1703,1732,1736,1741,1746,1752,1996,2002,2038,2043,2068,2099,2175,2191,2199,2215,2225,2237,2241],"first":[156,742],"multicenter":[157],"study":[158,226,1250,1625,2058],"characterize":[160],"safety":[162,263,1237,1819],"and":[163,209,234,281,307,400,435,475,496,505,531,556,598,659,688,704,733,784,825,972,988,1006,1017,1035,1049,1123,1210,1295,1367,1373,1402,1424,1446,1523,1569,1689,1727,1738,1743,1749,1845,1879,1904,1963,1993,1999,2026,2032,2079,2092,2121,2141,2147,2153,2158,2174],"feasibility":[164],"an":[166,292,1071,1203,1235,2105],"accelerated":[167,213,620,1199,1437,1534,1578,1655],"progression":[175,1395,1472],"relapsed/refractory":[177],"(R/R)":[178],"CLL.":[179,1397,1547],"This":[180,1300,2073,2111,2123],"retrospective":[181,1187,1670],"chart":[182,1188],"review":[183,1189,2146],"was":[184,245,321,345,379,404,593,599,673,779,792,803,811,820,886,918,961,1001,1253,1267,1284,1316,1537,1550,1675,1907],"conducted":[185],"across":[186],"four":[187],"large":[188],"academic":[189,1630],"medical":[190,223],"centers":[191,1631],"2019":[197],"2020.":[199],"Patients":[200,326],"R/R":[202,1195,1348,1546],"had":[205,210,291,311,327,549,737,747,1756,1988],"received":[206,526,537,985],"prior":[207,332,389,822,1143,1152,1165,1170],"documented":[212],"period":[216,227,552,1219,1251],"(<5":[217],"weeks)":[218],"were":[219,279,397,1127,1174,1229,1293,1409,1462,1567,1626,1766],"retrospectively":[220],"identified":[221,280],"charts.":[224],"began":[228],"1":[229,237,660,663,1037],"month":[230,238],"before":[231,347,391,648],"initiation":[233,979,1040],"continued":[235],"until":[236],"after":[239,500,665,1039,1047,1055],"completion.":[241],"primary":[243],"endpoint":[244],"proportion":[247,1555],"Grade":[251,411,443,1206],"\u22653":[252,1207],"adverse":[253],"events":[254,1292],"(AEs)":[255],"during":[256,361,529,1216],"chosen":[258],"capture":[260],"comprehensive":[262],"profile":[264],"setting.":[269,1617,1649],"Further":[270],"details":[271],"provided":[273,1676,2144],"Appendix":[275,2203],"S1.":[276],"Twenty-eight":[277],"included":[282,447],"analysis":[285,1238,2031],"(Table":[286,512,560,634,1067],"S1).":[287,340],"Seven":[288],"(25.0%)":[290,310],"absolute":[293],"lymphocyte":[294],"count":[295],"(ALC)":[296],"\u2265":[298,412,444],"\u00d7":[300],"109":[301],"cells/L":[302],"(median":[303],"27.5;":[304],"range":[305],"0.03\u20132160),":[306],"7":[308],"lymph":[312,1124],"node":[313,1125],"involvement":[314],">":[315],"cm.":[317],"Median":[318],"creatinine":[319,975,993],"clearance":[320],"84.0":[322],"mL/min":[323],"(range":[324,337,596,603,631,1420,1440],"51.0\u2013136.3).":[325],"median":[329,584,625,1256],"3":[331,413,445,555,1053],"lines":[333,1144],"therapy":[336,344,360,372,390,1146,1155,1166],"1\u20137;":[338],"Table":[339,417,522,679,954],"Last":[341],"line":[342,358,370,1153],"discontinued":[346,356,367,484,499,1214],"25":[351],"(89.3%).":[353],"One":[354],"patient":[355,402,498,535,984,1008,1118,1313,1479],"last":[357,369],"ramp-up.":[362,754],"Two":[363,695],"other":[364,1020,1434,1513,2088],"(7.1%)":[366,396,698],"their":[368],"once":[373],"stable":[375,494,567,589,612],"reached.":[380],"Among":[381],"these":[382],"three":[383,1240],"did":[386,490,709,771,1076,1106,1516,1570],"not":[387,491,710,772,1077,1107,1517,1571,1638,1908,2102,2212],"discontinue":[388],"initiation,":[393,658],"two":[394,489,689,951],"receiving":[398,405],"ibrutinib":[399],"one":[401,497,534,669,746,960],"(3.6%)":[403,661],"idelalisib.":[406],"Nine":[407],"(32.1%)":[409,652],"experienced":[410,674,699,764,973,1010,1032,1202,1629],"AEs":[414,446,1081,1228],"(primary":[415,1208],"endpoint;":[416],"S2),":[418],"including":[419,681],"anemia":[420],"(n":[421,426,431,438,449,454,460,465,471,477,545,1099,1108],"=":[422,427,432,439,450,455,461,466,472,478,546,1100,1109],"5;":[423],"17.9%),":[424],"neutropenia":[425,437],"2;":[428,451,456,462,467],"7.1%),":[429,452,457,463,468],"thrombocytopenia":[430],"1;":[433,440,473,479],"3.6%),":[434,474],"febrile":[436],"3.6%).":[441,480],"Additional":[442,1486],"hyperkalemia":[448],"hypocalcemia":[453],"hypovolemic":[458],"shock":[459,931],"lymphopenia":[464],"cardiovascular":[469],"insufficiency":[470],"hypophosphatemia":[476],"Three":[481,755],"(10.7%)":[483],"due":[486,1220,1226,1500],"AEs;":[488],"reach":[492,587,1259],"12":[501,2181],"days":[502,595,602,630,647,1046,1054,1272,1276],"maximum":[507],"S3).":[513],"schedules":[517,1439],"initiated":[518],"described":[520],"S4.":[523],"All":[524,617,1080,1754,1986],"antihyperuricemic":[527],"drugs":[528],"all":[532,761,1290,1565,1619,1759],"but":[533,1075,1428],"(96.4%)":[536],"intravenous":[538],"hydration.":[539],"majority":[541],"15,":[547],"53.6%)":[548],"between":[554,731,1724],"<":[557],"weeks":[559],"S5).":[561],"Twenty-six":[562],"(92.9%)":[564],"reached":[565,576,610],"venetoclax;":[570],"these,":[572],"(71.4%)":[575],"mg.":[582,616,1062],"time":[585,1257,2173],"any":[588,774,2131,2172,2220],"21":[594,601,1271],"11\u201325)":[597],"also":[600],"18\u201325)":[604],"underwent":[619],"inpatients,":[623],"hospital":[626,638],"stay":[627],"11":[629],"4\u201328)":[632],"overall":[633],"S4).":[635],"Timing":[636],"admission":[639],"varied,":[640],"18":[642],"(64.3%)":[644],"admitted":[645,653,662],"1\u20135":[646],"initiation;":[650,1048],"9":[651],"day":[656,664,1038],"initiation.":[666],"At":[667],"least":[668],"AE":[670,767,1204],"TLS":[672,686,693,717,727,770,778,785,969,1029,1083,1098,1283,1291,1305,1389,1404,1423,1445,1549],"by":[675,1311,1677,1691,1713,2130,2224],"seven":[676,723],"(25.0%;":[678],"1),":[680],"five":[682,757],"cases":[683,690,1566],"laboratory":[685,716,769,990,1401,1422,1444],"(17.9%)":[687],"clinical":[692,958,1085,1090,1298,1403,1426,1450,1575,1652,1883,2069,2115,2124],"(7.1%).":[694],"additional":[696],"metabolic":[700],"abnormalities":[701],"(hyperuricemia,":[702],"hypocalcemia,":[703,1034],"acute":[705,1013,1050],"kidney":[706,864,942,1014,1051],"disease)":[707],"that":[708,1113,1337,1345,1515,1640],"meet":[711],"Howard":[713,1519],"Criteria":[714,1520],"investigator":[719],"assessment.":[720],"Of":[721,949],"developed":[726,957,1097,1721],"(at":[728],"doses":[729],"ranging":[730],"mg),":[735],"six":[736],"event":[738],"onset":[739,748],"within":[740,997],"week":[743,752],"ramp-up;":[745],"second":[751],"(10.7%":[759],"patients)":[762],"single":[766,1057],"receive":[773,1355,1363],"interventions":[775,1066],"because":[776],"self-limited":[780],"ongoing":[782,2106],"hydration":[783,987,1372],"prophylaxis.":[786],"Hyperkalemia":[787,806,877,909],"(1)cc":[788],"Whole":[789,808,883,915],"blood":[790,809,884,916],"potassium":[791,810,827,885,917],"checked":[793,812,887,919],"confirm":[795,814,889,921],"true":[796,815,890,922],"hyperkalemia.":[797,816,891,923,1018],"[Pre:":[798,838,844,850,856,867,873,879,899,905,911,935,945],"4.2;":[799,857],"Max:":[800,840,846,852,869,875,881,901,907,913,937,947],"6.1dd":[801],"Sample":[802],"hemolyzed.":[804],"]":[805,892,924],"(2)cc":[807],",ee":[817],"Significant":[818],"pseudohyperkalemia":[819,832],"observed":[821,1233,1285,1304,1551],"dosing,":[824,831],"although":[826,1248],"measurements":[828],"following":[830,977,1473,2145,2200],"may":[833,1481,1581,1955],"still":[834],"have":[835,1482],"been":[836],"present.":[837],"5.1;":[839],"8.5]":[841],"Hypocalcemia":[842,903],"(4)":[843,866,872,878,898,904,910,932,934,944],"1.07;":[845],"1.17]":[847],"Hyperphosphatemia":[848,854,859,871,897],"(2)":[849],"3.8;":[851],"5.6]":[853],"(1)":[855,860],"Max:7.2]":[858],"[Pre:3.8;":[861],"Max:5.3]":[862],"Acute":[863,941],"injury":[865,943,1052],"1.2;":[868],"1.57]":[870],"3.3;":[874],"6.4]":[876],"3.9;":[880,936],"6.0cc":[882],"Calcium":[893,925,927],"gluconate":[894,926],"Polyethylene":[895],"glycol":[896],"5.7;":[900],"11.2]":[902],"8.8;":[906],"7.3]":[908],"4.0;":[912],"6.1cc":[914],"chloride":[928],"Dialysis":[929],"Hypovolemic":[930],"Hyperuricemia":[933],"5.5]":[938],"Allopurinol":[939],"Rasburicase":[940],"1.3;":[946],"1.55]":[948],"(7.1%;":[953],"1)":[955,1068],"TLS,":[959,1522],"assessed":[962,1022,1463],"being":[964,1024,1720],"at":[965,970,1025,1030,1270,1466,1628,2171],"high":[966,1301,1319],"baseline,":[971,1031],"levels":[976],"(20":[980],"dose);":[982],"close":[989,1531,1633],"monitoring,":[991,1533,1635],"returning":[994],"baseline":[996,1117],"24":[998],"h.":[999],"escalated":[1002],"then":[1009],"grade":[1011],"4":[1012],"injury,":[1015],"hyperphosphatemia,":[1016,1033],"patient,":[1021],"medium":[1026],"hyperkalemia,":[1036],"monotherapy;":[1043],"hyperuricemia":[1044],"2":[1045],"initial":[1058],"Both":[1063],"required":[1065],"administered":[1069],"intensive":[1072],"care":[1073],"unit":[1074],"require":[1078,1338],"hemodialysis.":[1079],"(including":[1084,1121],"events)":[1086],"resolved":[1087],"without":[1088,1297],"long-term":[1089,1574],"sequelae.":[1091,1299,1576],"Between-group":[1092],"comparisons":[1093],"7,":[1101],"25.0%)":[1102],"versus":[1103],"21,":[1110],"75.0%)":[1111],"reveal":[1112],"none":[1114],"characteristics":[1119],"analyzed":[1120],"ALC":[1122],"size)":[1126],"significantly":[1128],"associated":[1129,1178,1413],"subsequent":[1131],"TLS.":[1134,1183,1322,1379],"None":[1135],"genetic":[1138],"features":[1139],"analyzed,":[1140],"number":[1141],"(\u22643":[1147],"or":[1148,1158,1160,1169,1593,1764,1817,1958,2055,2107,2193,2217],">3),":[1149],"type":[1150],"(BCRis,":[1156],"chemoimmunotherapy,":[1157],"other),":[1159],"timing":[1161],"discontinuation":[1163,1225,1474],"(during/after":[1167],"initiation)":[1173],"found":[1175],"be":[1177,1307,1465,1644,2128,2143,2169,2178,2234],"development":[1181],"In":[1184],"multicenter,":[1186],"study,":[1190,1507,1733],"32.1%":[1191],"treated":[1197,1627],"endpoint),":[1209],"10.7%":[1211],"AEs.":[1222],"Rates":[1223],"similar":[1230],"integrated":[1236],"phase":[1241],"1/2":[1242],"studies":[1243,1435,1514,1884],"monotherapy":[1246],"(10.0%),":[1247],"here":[1252],"shorter.6":[1254],"substantially":[1268],"shorter":[1269,1599],"than":[1273,1411,1430,1558,1609,2230],"35":[1275],"schedule.":[1281],"one-quarter":[1287],"patients,":[1289],"manageable":[1294,1568],"recovered":[1296],"rate":[1302],"could":[1306,1354],"explained":[1308],"part":[1310,1685,2103],"selection,":[1314],"which":[1315,1886],"enriched":[1317],"These":[1323],"confirmatory":[1324],"findings":[1325,1667],"will":[1326,2142,2177],"help":[1327],"inform":[1329],"future":[1330],"changes":[1331],"urgent":[1340],"treatment.":[1341],"Our":[1342,1453],"indicate":[1344],"requiring":[1350],"acceleration":[1360],"if":[1361],"they":[1362],"inpatient":[1365,1532,1605,1634],"monitoring":[1366,1820],"administration":[1368],"adequate":[1370],"prophylactic":[1371],"antihyperuricemics":[1374],"reduce":[1376],"decision-making":[1381],"should":[1382,2233],"balance":[1383],"possible":[1385,2184],"rates":[1399,1431],"noted":[1405],"our":[1407,1498,1524,1624,1641,1669],"cohort":[1408],"higher":[1410,1467,1554],"0%\u20132.6%":[1421],"0%\u20130.5%":[1425],"TLS)":[1427],"lower":[1429],"reported":[1432,1561],"up":[1441,1447],"52%":[1443],"15%":[1449],"TLS).1-3,":[1451],"describes":[1455],"select":[1457],"group":[1458],"BCRi":[1476,1591],"therapy;":[1477],"therefore,":[1478],"selection":[1480],"affected":[1483],"results.":[1485],"limitations":[1487],"include":[1488],"heterogeneity":[1490],"used":[1496],"real-world":[1503],"nature":[1504],"challenge":[1509],"comparing":[1511],"use":[1518],"relatively":[1525],"small":[1526],"sample":[1527],"size.":[1528],"Overall,":[1529],"feasible":[1538],"population":[1541],"commonly":[1560],"result":[1572],"particularly":[1587],"progressing":[1589],"on/after":[1590],"therapy,":[1592],"would":[1596],"find":[1597],"performed":[1602],"setting":[1606],"convenient":[1608],"outpatient":[1616],"As":[1618],"we":[1636,2071],"do":[1637],"believe":[1639],"can":[1643,2127,2168],"extrapolated":[1645],"outside":[1646],"A":[1650],"prospective":[1651],"trial":[1653,2116,2125],"now":[1661],"underway":[1662],"(NCT04843904)":[1663],"validate":[1665],"study.":[1671],"Medical":[1672],"writing":[1673],"support":[1674],"Hayley":[1678],"Ellis,":[1679],"PhD,":[1680],"Fishawack":[1682,1687],"Communications":[1683],"Ltd,":[1684],"Health,":[1688],"funded":[1690],"AbbVie.":[1692],"Matthew":[1693,1770,2004],"S.":[1694,1771,2005],"Davids":[1695],"Scholar":[1698],"Research":[1701,1848,1866,1938,1973],"Leukemia":[1704],"&":[1705],"Lymphoma":[1706],"Society.":[1707],"Jennifer":[1708,1936,2014],"L.":[1709,2015],"Crombie":[1710],"supported":[1712],"K12":[1715],"(K12CA087723).":[1716],"(ABT-199/GDC-0199)":[1718],"collaboration":[1723],"AbbVie,":[1725,1729,1878],"Inc.,":[1726],"Genentech.":[1728],"Inc.":[1730],"sponsored":[1731],"contributed":[1734],"analysis,":[1737],"interpretation":[1739,2033],"data,":[1742,1992],"participated":[1744,1994],"writing,":[1747,1997],"review,":[1748,1998],"approval":[1750,2000,2148],"manuscript.":[1753,2003],"authors":[1755,1987],"access":[1757,1989,2075],"relevant":[1760,1991],"data.":[1761],"No":[1762],"honoraria":[1763],"payments":[1765],"made":[1767],"authorship.":[1769],"Davids:":[1772],"Institutional":[1773],"research":[1774,2151],"grants\u2014Ascentage":[1775],"Pharma,":[1776,1781,1794,1804,1839,1841,1901],"AstraZeneca,":[1777,1795,1823,1861,1874,1897,1917,1923,1966,1977],"BMS,":[1778,1797],"Genentech,":[1779,1801,1822,1856,1898,1927,1969,1979],"MEI":[1780,1803],"Novartis,":[1782],"Pharmacyclics,":[1783,1826,1854,1872],"Surface":[1784],"Oncology,":[1785],"TG":[1786,1807,1836,1858,1875,1933,1983],"Therapeutics,":[1787,1808,1829,1837,1859,1876,1934,1984],"Verastem.":[1788,1809,1935,1985],"Consulting":[1789,1962],"fees\u2014AbbVie,":[1790],"Adaptive":[1791,1842,1902],"Biotechnologies,":[1792,1843,1903],"Ascentage":[1793,1880],"BeiGene,":[1796,1830,1860,1967,1978],"Celgene,":[1798,1851,1968],"Eli":[1799],"Lilly,":[1800,1920],"Janssen,":[1802,1873,1971],"Merck,":[1805,1835,1877,1944],"Takeda,":[1806],"Mazyar":[1810,2007],"Shadman:":[1811],"Consulting,":[1812],"advisory":[1813,1964],"boards,":[1814],"steering":[1815],"committees":[1816],"committees\u2014AbbVie,":[1821],"Sound":[1824],"Biologics,":[1825],"Verastem,":[1827],"ADC":[1828],"Cellectar,":[1831],"Bristol-Myers":[1832,1852],"Squibb,":[1833,1853],"Morphosys,":[1834],"Innate":[1838,1900],"Kite":[1840],"Epizyme,":[1844,1926],"Atara":[1846],"Biotherapeutics.":[1847],"funding\u2014Mustang":[1849],"Bio,":[1850],"Gilead,":[1855,1970],"Abbvie,":[1857],"Sunesis.":[1862],"Sameer":[1863,1887,2009],"A.":[1864,1888,2010],"Parikh:":[1865],"funding":[1867,1939,1974],"(provided":[1868,1940],"institution)":[1870],"Pharma":[1881],"Parikh":[1889],"principal":[1892],"investigator.":[1893],"Advisory":[1894],"board":[1895],"meetings\u2014Pharmacyclics,":[1896],"GlaxoSmithKline,":[1899],"AbbVie":[1905,2060],"(he":[1906],"personally":[1909],"compensated":[1910],"his":[1912],"participation).":[1913],"Chaitra":[1914,2012],"Ujjani:":[1915],"Research\u2014AbbVie,":[1916],"Gilead/Kite,":[1918,1928],"Loxo/Eli":[1919],"PYC.":[1921],"Consulting\u2014AbbVie,":[1922],"Atara,":[1924],"Beigene,":[1925],"Incyte,":[1929],"Jannsen,":[1930],"MorphoSys,":[1931],"PYC,":[1932],"Crombie:":[1937],"institution)\u2014AbbVie,":[1942,1976],"Bayer,":[1943],"Roche.":[1945],"Consulting\u2014Incyte,":[1946],"Karyopharm.":[1947],"Dingfeng":[1948,2017],"Jiang,":[1949,2018],"Cynthia":[1950,2019],"Llamas,":[1951,2020],"Dai":[1952,2021],"Feng:":[1953],"Employees\u2014AbbVie,":[1954],"hold":[1956],"stock":[1957],"options.":[1959],"Nicole":[1960,2023],"Lamanna:":[1961],"boards\u2014AbbVie,":[1965],"Pharmacyclics.":[1972],"(to":[1975],"Juno,":[1980],"MingSight,":[1981],"Oncternal,":[1982],"Davids,":[2006],"Shadman,":[2008],"Parikh,":[2011],"Ujjani,":[2013],"Crombie,":[2016],"Feng,":[2022],"Lamanna\u2014study":[2024],"concept":[2025],"design;":[2027],"acquisition":[2028],"data;":[2030,2035],"drafting":[2036],"manuscript;":[2039],"critical":[2040],"revision":[2041],"manuscript":[2044],"important":[2046],"intellectual":[2047],"content;":[2048],"statistical":[2049],"analysis;":[2050],"obtained":[2051],"funding;":[2052],"administrative,":[2053],"technical,":[2054],"material":[2056],"support;":[2057],"supervision.":[2059],"committed":[2062],"responsible":[2064,2213],"sharing":[2066],"regarding":[2067],"trials":[2070,2100],"sponsor.":[2072],"includes":[2074,2112],"anonymized,":[2077],"individual,":[2078],"trial-level":[2080],"(analysis":[2082],"sets),":[2084],"information":[2089,2189,2222],"(eg,":[2090],"protocols":[2091],"Study":[2094],"Reports),":[2095],"long":[2097],"planned":[2108],"regulatory":[2109],"submission.":[2110],"requests":[2113,2167],"unlicensed":[2119],"products":[2120],"indications.":[2122],"requested":[2129],"qualified":[2132],"researchers":[2133],"engage":[2135],"rigorous,":[2137],"independent":[2138],"scientific":[2139],"research,":[2140],"proposal":[2152],"Statistical":[2154],"Analysis":[2155],"Plan":[2156],"(SAP)":[2157],"execution":[2159],"Data":[2162,2166],"Sharing":[2163],"Agreement":[2164],"(DSA).":[2165],"submitted":[2170],"accessible":[2179],"months,":[2182],"extensions":[2185],"considered.":[2186],"For":[2187],"process,":[2192],"submit":[2195],"request,":[2197],"visit":[2198],"link:":[2201],"https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html.":[2202],"S1:":[2204],"Supporting":[2205],"Please":[2207],"note:":[2208],"publisher":[2210],"content":[2216],"functionality":[2218],"supporting":[2221],"supplied":[2223],"authors.":[2226],"Any":[2227],"queries":[2228],"(other":[2229],"missing":[2231],"content)":[2232],"directed":[2235],"corresponding":[2238],"author":[2239],"article.":[2242]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-12-31T00:00:00"}